There are currently 172 clinical trials in El Paso, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including El Paso Children's Hospital, Texas Tech University Health Sciences Center, GSK Investigational Site and Texas Tech University Health Sciences Center El Paso. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
NCT05669833
Recruiting
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/23/2024
Locations: Texas Arthritis Center, El Paso, Texas
Conditions: Psoriatic Arthritis
Register for Updates
Impact of Direct Current Electrical Stimulation on Treatment of Lumbosacral Radiculopathy
NCT06421558
Recruiting
This study will compare two methods of electrical stimulation (alternating current and direct current) as an adjunctive therapy to treating lumbosacral radiculopathy. Both types of electrical stimulation have been used in clinical practice for physical therapy, however direct current stimulation is much less common and there is less known about its impact on physical therapy outcomes. The aim of this project is to show the efficacy of a novel device, the Neubie direct current device, compared to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2024
Locations: Spine & Rehab Specialists, El Paso, Texas +1 locations
Conditions: Radiculopathy Lumbar, Radiculopathy Sacral, Radiculopathy Multiple Sites
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Renovatio Clinical - El Paso, El Paso, Texas
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
VIGOR: Virtual Genome Center for Infant Health
NCT05205356
Recruiting
This study will provide rigorous evaluation of implementing a virtual genome center into community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minority (URM) populations and will enhance capacity for providers and health systems to utilize highly sp... Read More
Gender:
ALL
Ages:
Between 0 days and 99 years
Trial Updated:
06/21/2024
Locations: The Hospitals of Providence, El Paso, Texas
Conditions: Genetics Disease, Genetics/Birth Defects, Genetic Predisposition to Disease
Register for Updates
Trial of a Culturally Informed Brief Intervention to Reduce Alcohol Related Health Disparities and Treatment Inequities Among Latinxs
NCT05800899
Recruiting
This Stage II Randomized Efficacy Trial will compare the effectiveness of a theoretically informed and culturally responsive brief motivational intervention to a non-adapted brief intervention among non-treatment seeking Latinxs admitted for medical treatment of an injury who engage in at risk drinking or were drinking at the time of their injury. The culturally informed brief motivational intervention (CI-BMI) increases autonomous motivation to engage in protective drinking behavior and reduce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University Medical Center of El Paso, El Paso, Texas
Conditions: Alcohol Use Disorder
Register for Updates
Multi-analyte Blood Test Clinical Trial
NCT05199259
Recruiting
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Texas Gastro Research, El Paso, Texas
Conditions: Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
Register for Updates
IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery
NCT05954767
Recruiting
This study evaluates the safety and efficacy of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2024
Locations: The Hospital of Providence Transmountain Campus, El Paso, Texas
Conditions: Ureter Injury
Register for Updates
IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact
NCT04221815
Recruiting
Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI. This is accomplished by improving the angiographic result with lesion and vessel assessment to guide stent selection and implantation and intravascular imaging following stent implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive literature supporting the use of IVUS in PCI, util... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Texas Tech University Health Sciences Center, El Paso, Texas
Conditions: Atherosclerosis
Register for Updates
Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention
NCT05120869
Recruiting
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV). Our hypothesis is that improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among the populations they serve.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2024
Locations: The University of Texas at El Paso, Border Biomedical Research Center, El Paso, Texas
Conditions: Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Register for Updates
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
NCT06403605
Recruiting
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC treatments for Diabetic Foot Wounds.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: PULSE: Amputation Prevention Center, LLC, El Paso, Texas
Conditions: Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
Register for Updates
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
NCT05049057
Recruiting
This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/21/2024
Locations: William Beaumont Army Medical Center, El Paso, Texas
Conditions: Posttraumatic Headache, Mild Traumatic Brain Injury
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Gastro Clinic, El Paso, Texas
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates